SG11201507669YA - Peptide vaccine for prevention and immunotherapy of dementia of the alzheimer's type - Google Patents
Peptide vaccine for prevention and immunotherapy of dementia of the alzheimer's typeInfo
- Publication number
- SG11201507669YA SG11201507669YA SG11201507669YA SG11201507669YA SG11201507669YA SG 11201507669Y A SG11201507669Y A SG 11201507669YA SG 11201507669Y A SG11201507669Y A SG 11201507669YA SG 11201507669Y A SG11201507669Y A SG 11201507669YA SG 11201507669Y A SG11201507669Y A SG 11201507669YA
- Authority
- SG
- Singapore
- Prior art keywords
- immunotherapy
- dementia
- alzheimer
- prevention
- type
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0007—Nervous system antigens; Prions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/34—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Corynebacterium (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
- C12N2760/18434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Neurology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Toxicology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Dermatology (AREA)
- Virology (AREA)
- General Engineering & Computer Science (AREA)
- Hospice & Palliative Care (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13/843,883 US9102752B2 (en) | 2013-03-15 | 2013-03-15 | Peptide vaccine for prevention and immunotherapy of dementia of the Alzheimer's type |
| PCT/US2013/037865 WO2014143087A1 (en) | 2013-03-15 | 2013-04-23 | Peptide vaccine for prevention and immunotherapy of dementia of the alzheimer's type |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201507669YA true SG11201507669YA (en) | 2015-10-29 |
Family
ID=51527985
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201507669YA SG11201507669YA (en) | 2013-03-15 | 2013-04-23 | Peptide vaccine for prevention and immunotherapy of dementia of the alzheimer's type |
Country Status (19)
| Country | Link |
|---|---|
| US (4) | US9102752B2 (pt) |
| EP (1) | EP2968485B1 (pt) |
| JP (3) | JP6208319B2 (pt) |
| KR (2) | KR20180132962A (pt) |
| CN (2) | CN105228644B (pt) |
| AU (3) | AU2013381835A1 (pt) |
| BR (1) | BR112015023105A8 (pt) |
| CA (1) | CA2906313A1 (pt) |
| DK (1) | DK2968485T3 (pt) |
| ES (1) | ES2800028T3 (pt) |
| HK (1) | HK1212600A1 (pt) |
| IL (2) | IL241597B (pt) |
| MX (2) | MX364689B (pt) |
| PT (1) | PT2968485T (pt) |
| RU (1) | RU2696566C2 (pt) |
| SG (1) | SG11201507669YA (pt) |
| TW (1) | TWI561529B (pt) |
| WO (1) | WO2014143087A1 (pt) |
| ZA (2) | ZA201507526B (pt) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9102752B2 (en) * | 2013-03-15 | 2015-08-11 | United Biomedical, Inc. | Peptide vaccine for prevention and immunotherapy of dementia of the Alzheimer's type |
| AU2015243990A1 (en) * | 2014-04-07 | 2016-11-10 | La Jolla Pharmaceutical Company | Hepcidin mimetic peptides and uses thereof |
| EP3409130B1 (en) * | 2016-01-27 | 2020-11-25 | Industry-Academic Cooperation Foundation Gyeongsang National University | Composition for preventing, alleviating or treating neurological disorders, containing, as active ingredient, novel peptide activating adiponectin receptors |
| US20210214406A1 (en) * | 2016-04-14 | 2021-07-15 | Tao Health Life Pharma Co., Ltd. | Amylospheroid (aspd)-like structure and pharmaceutical composition |
| CN106565847B (zh) * | 2016-10-26 | 2020-12-01 | 清华大学 | 化合物、多肽及其用途 |
| KR20200054938A (ko) * | 2017-06-16 | 2020-05-20 | 유나이티드 뉴로사이언스 | 알파-시뉴클린 단백질의 c-말단부로부터의 펩티드 면역원 및 시뉴클레인병증 치료를 위한 그의 제형화 |
| SG11202003624SA (en) * | 2017-10-27 | 2020-05-28 | United Neuroscience | Tau peptide immunogen constructs |
| EP3724218A2 (en) * | 2017-12-11 | 2020-10-21 | UBI IP Holdings | Peptide immunogens of il-31 and formulations thereof for the treatment and/or prevention of atopic dermatitis |
| SG11202006215TA (en) * | 2017-12-31 | 2020-07-29 | United Biomedical Inc | Peptide immunogens and formulations thereof targeting membrane-bound ige for treatment of ige mediated allergic diseases |
| JP2021514361A (ja) * | 2018-02-13 | 2021-06-10 | シーダーズ—シナイ メディカル センター | 病的神経変性及び加齢性認知機能低下の特定及び処置のための方法及び系 |
| CN112218655A (zh) * | 2018-05-04 | 2021-01-12 | Ubi Ip 控股公司 | 以人工混合t辅助细胞表位以有限度的t细胞炎性反应促进目标抗体的生产 |
| TWI676635B (zh) * | 2018-06-15 | 2019-11-11 | 英屬開曼群島商聯腦科學公司 | α－突觸核蛋白Ｃ端胜肽免疫原及其用於治療突觸核蛋白疾病的配方 |
| JP2022514668A (ja) * | 2018-12-19 | 2022-02-14 | ユナイテッド・バイオメディカル・インコーポレーテッド | 合成ペプチド免疫原のための免疫刺激薬としての人工無差別ｔヘルパー細胞エピトープ |
| EP3902554A4 (en) * | 2018-12-28 | 2022-12-14 | United Biomedical Inc. | INTERLEUKIN 6 (IL-6) TARGETING PEPTIDE IMMUNOGENS AND RELATED FORMULATIONS FOR THE IMMUNOTHERAPY OF DISEASES IMPACTED BY IL-6 DYSREGULATION |
| SG11202107046YA (en) * | 2018-12-31 | 2021-07-29 | United Neuroscience Ltd | Peptide immunogens targeting calcitonin gene-related peptide (cgrp) and formulations thereof for prevention and treatment of migraine |
| CN110759987B (zh) * | 2019-10-29 | 2021-06-08 | 中国人民解放军军事科学院军事医学研究院 | 构象特异性的重组Aβ1-42样寡聚体抗原、其制备方法和应用 |
| CA3168991A1 (en) * | 2020-01-23 | 2021-07-29 | United Biomedical, Inc. | Peptide immunogens targeting pituitary adenylate cyclase-activating peptide (pacap) and formulations thereof for prevention and treatment of migraine |
| KR20230016164A (ko) | 2020-03-10 | 2023-02-01 | 라이프아크 | 시클릭 펩티드 |
| CN116635517A (zh) * | 2020-11-17 | 2023-08-22 | 伊利亚德生物技术有限公司 | 与神经退行性疾病相关的神经病理的治疗和预防 |
| US20240159777A1 (en) * | 2021-03-16 | 2024-05-16 | Neurovision Imaging, Inc. | Biofluid-Based Methods for Diagnosing Alzheimer’s Disease-Associated Conditions |
| WO2023034324A2 (en) * | 2021-08-30 | 2023-03-09 | The Brigham And Women’S Hospital, Inc. | Methods and materials to treat neurodegenerative disease |
| WO2023161526A1 (en) | 2022-02-28 | 2023-08-31 | Tridem Bioscience Gmbh & Co Kg | A CONJUGATE CONSISTING OF OR COMPRISING AT LEAST A ß-GLUCAN OR A MANNAN |
| KR102530956B1 (ko) * | 2022-09-08 | 2023-05-11 | 주식회사 알츠코리아 | 아밀로이드 베타 유래 에피토프를 유효성분으로 포함하는 알츠하이머성 치매 백신 조성물 및 이의 용도 |
| CN115417915B (zh) * | 2022-11-03 | 2023-02-24 | 北京引正基因科技有限公司 | 多肽载体及其应用 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5753624A (en) | 1990-04-27 | 1998-05-19 | Milkhaus Laboratory, Inc. | Materials and methods for treatment of plaquing disease |
| JP2980677B2 (ja) | 1990-04-27 | 1999-11-22 | マクマイケル，ジョン | 不正常なアミロイドβタンパク質と関連する中枢神経系疾患状態の治療のための方法および組成物 |
| EP1308461A3 (en) | 1993-01-25 | 2004-02-11 | Takeda Chemical Industries, Ltd. | Antibodies to beta-amyloids or their derivatives and use thereof |
| US5955317A (en) | 1993-01-25 | 1999-09-21 | Takeda Chemical Industries, Ltd. | Antibodies to β-amyloids or their derivatives and use thereof |
| US5759551A (en) | 1993-04-27 | 1998-06-02 | United Biomedical, Inc. | Immunogenic LHRH peptide constructs and synthetic universal immune stimulators for vaccines |
| WO1994028412A1 (en) | 1993-05-28 | 1994-12-08 | The Miriam Hospital | Composition and method for in vivo imaging of amyloid deposits |
| EP0725838A4 (en) | 1993-10-26 | 1997-02-26 | United Biomedical Inc | STRUCTURED SYNTHETIC ANTIGAN BANKS AS DIAGNOSTICS, VACCINE AND THERAPEUTIC AGENTS |
| US6787523B1 (en) | 1997-12-02 | 2004-09-07 | Neuralab Limited | Prevention and treatment of amyloidogenic disease |
| US7964192B1 (en) | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
| TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
| US6750324B1 (en) | 1997-12-02 | 2004-06-15 | Neuralab Limited | Humanized and chimeric N-terminal amyloid beta-antibodies |
| TWI229679B (en) | 1998-06-20 | 2005-03-21 | United Biomedical Inc | Artificial T helper cell epitopes as immune stimulators for synthetic peptide immunogens |
| US6025468A (en) | 1998-06-20 | 2000-02-15 | United Biomedical, Inc. | Artificial T helper cell epitopes as immune stimulators for synthetic peptide immunogens including immunogenic LHRH peptides |
| US6919075B1 (en) | 1999-09-03 | 2005-07-19 | Ramot At Tel Aviv University Ltd. | Bacteriophage displaying aβ epitopes and method of use |
| EP1237930B1 (en) | 1999-12-08 | 2006-11-08 | Intellect Neurosciences, Inc. | Chimeric amyloid beta peptides |
| US20030083277A1 (en) * | 2000-02-24 | 2003-05-01 | Hersh Louis B. | Use of insulin degrading enzyme (IDE) for the treatment of alzheimer's disease in patients |
| US20030165481A1 (en) | 2000-02-24 | 2003-09-04 | Hersh Louis B. | Amyloid peptide inactivating enzyme to treat Alzheimer's disease |
| US6906169B2 (en) | 2001-05-25 | 2005-06-14 | United Biomedical, Inc. | Immunogenic peptide composition comprising measles virus Fprotein Thelper cell epitope (MUFThl-16) and N-terminus of β-amyloid peptide |
| US8088388B2 (en) | 2002-02-14 | 2012-01-03 | United Biomedical, Inc. | Stabilized synthetic immunogen delivery system |
| EP1523499A2 (en) * | 2002-07-24 | 2005-04-20 | Innogenetics N.V. | Fragments of beta-amyloid as targets for vaccination against alzheimer disease |
| WO2005072777A2 (en) * | 2004-01-28 | 2005-08-11 | Curix Aps | Conjugates of amyloid proteins as vaccines for amyloid-related diseases |
| KR20080103560A (ko) * | 2006-02-22 | 2008-11-27 | 가부시끼가이샤 하야시바라 세이부쓰 가가꾸 겐꾸조 | 항 아밀로이드-β-펩티드 항체 생산 유도용 펩티드 백신 |
| MX2008010633A (es) * | 2006-02-24 | 2008-09-25 | Chiesi Farma Spa | Composiciones inmunogenicas anti-amiloides, metodos y usos. |
| US20090123488A1 (en) | 2006-08-14 | 2009-05-14 | Thymon, Llc | Compositions and methods for the treatment and prophylaxis of Alzheimer's disease |
| AT506820B1 (de) * | 2008-06-12 | 2011-07-15 | Affiris Forschungs Und Entwicklungs Gmbh | Vakzine gegen alzheimer-krankheit |
| EP2342356A4 (en) * | 2008-09-29 | 2012-11-21 | Univ Ben Gurion | AMYLOID BETA PEPTIDASES AND METHOD OF USE THEREOF |
| US9067981B1 (en) * | 2008-10-30 | 2015-06-30 | Janssen Sciences Ireland Uc | Hybrid amyloid-beta antibodies |
| WO2012056008A1 (en) * | 2010-10-28 | 2012-05-03 | Jonas Nilsson | Diagnosis and treatment of alzheimer's disease |
| US9102752B2 (en) * | 2013-03-15 | 2015-08-11 | United Biomedical, Inc. | Peptide vaccine for prevention and immunotherapy of dementia of the Alzheimer's type |
-
2013
- 2013-03-15 US US13/843,883 patent/US9102752B2/en active Active
- 2013-04-23 KR KR1020187034866A patent/KR20180132962A/ko not_active Application Discontinuation
- 2013-04-23 CN CN201380076473.3A patent/CN105228644B/zh active Active
- 2013-04-23 DK DK13878092.9T patent/DK2968485T3/da active
- 2013-04-23 WO PCT/US2013/037865 patent/WO2014143087A1/en active Application Filing
- 2013-04-23 JP JP2016500078A patent/JP6208319B2/ja active Active
- 2013-04-23 RU RU2015142996A patent/RU2696566C2/ru active IP Right Revival
- 2013-04-23 SG SG11201507669YA patent/SG11201507669YA/en unknown
- 2013-04-23 CN CN201810667175.6A patent/CN108794615A/zh active Pending
- 2013-04-23 EP EP13878092.9A patent/EP2968485B1/en active Active
- 2013-04-23 BR BR112015023105A patent/BR112015023105A8/pt not_active Application Discontinuation
- 2013-04-23 KR KR1020157029184A patent/KR101926030B1/ko active IP Right Grant
- 2013-04-23 PT PT138780929T patent/PT2968485T/pt unknown
- 2013-04-23 CA CA2906313A patent/CA2906313A1/en not_active Abandoned
- 2013-04-23 MX MX2015013235A patent/MX364689B/es active IP Right Grant
- 2013-04-23 AU AU2013381835A patent/AU2013381835A1/en not_active Abandoned
- 2013-04-23 ES ES13878092T patent/ES2800028T3/es active Active
-
2014
- 2014-03-14 TW TW103109373A patent/TWI561529B/zh active
-
2015
- 2015-08-11 US US14/824,075 patent/US20160068581A1/en not_active Abandoned
- 2015-09-15 MX MX2019005268A patent/MX2019005268A/es unknown
- 2015-09-16 IL IL241597A patent/IL241597B/en active IP Right Grant
- 2015-10-09 ZA ZA2015/07526A patent/ZA201507526B/en unknown
-
2016
- 2016-01-18 HK HK16100507.8A patent/HK1212600A1/zh unknown
-
2017
- 2017-05-22 AU AU2017203425A patent/AU2017203425B2/en not_active Ceased
- 2017-06-07 JP JP2017112424A patent/JP6784646B2/ja active Active
-
2018
- 2018-04-19 US US15/957,798 patent/US20180244739A1/en not_active Abandoned
- 2018-12-31 US US16/237,531 patent/US20190194280A1/en not_active Abandoned
-
2019
- 2019-04-08 IL IL265910A patent/IL265910A/en unknown
- 2019-07-26 JP JP2019137534A patent/JP2019196397A/ja active Pending
- 2019-10-10 ZA ZA2019/06683A patent/ZA201906683B/en unknown
- 2019-10-11 AU AU2019246916A patent/AU2019246916A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201906683B (en) | Peptide vaccine for prevention and immunotherapy of dementia of the alzheimer's type | |
| EP2951158A4 (en) | PROCESS FOR THE PREPARATION OF IVACAFTOR AND SOLVATES THEREOF | |
| HK1254054A1 (zh) | 富馬酸二甲酯顆粒和其藥物組合物 | |
| IL287985A (en) | A peptide derived from koc1 and a component containing it | |
| IL284792A (en) | Peptide derivative - DEPDC1 and a component containing it | |
| GB201423272D0 (en) | The combination for anti-wrinkle and soothing the skin | |
| IL248711A (en) | Epixaben glycol esters as major intermediates and impurities in the process of epixaben synthesis | |
| IL265269B (en) | New compounds and their medicinal uses | |
| HK1246271A1 (zh) | 用於合成羥基-三甘油酯的方法及其用於預防和治療疾病的用途 | |
| IL258700A (en) | An excipient and a vaccine that includes it | |
| HUE047778T2 (hu) | Dezmoglein 3 peptidek Pemphigus vulgarisban | |
| IL250215B (en) | A peptide derived from cdca1 and a component containing it | |
| IL251289A0 (en) | New peptide derivatives and their use | |
| EP3102590A4 (en) | Antigenic epitopes from ebv gp350/220 and uses thereof | |
| IL250235A0 (en) | A peptide derived from urlc10 and a component containing it | |
| GB201421888D0 (en) | Peptides derived from mysoin 19 and methods of use thereof | |
| GB201615560D0 (en) | Novel compounds and therapeutic uses thereof | |
| GB201402040D0 (en) | Tie 'Not |